Purpose of Review: This article reviews the standard treatment of patients with high-grade glioma primary brain tumors and discusses promising new therapeutic advances. Recent Findings: While surgery and radiation remain critical components of the management of patients with high-grade gliomas, chemotherapy has recently been proven to improve the overall survival of patients with glioblastomas and anaplastic oligodendrogliomas. Molecular markers are complementing clinical prognostic factors and, in some cases, are able to guide treatment decisions. Despite aggressive treatment, high-grade gliomas eventually progress, emphasizing the importance of continued development of novel therapies for the treatment of this deadly disease. Summary: The care of patients with high-grade gliomas is challenging, but the experience is highly rewarding. Rapidly developing technology allows for the use of molecular data for improved classification of high-grade gliomas and is beginning to improve our understanding of the pathogenesis and drivers of this disease. Collaboration among investigators will be critical to effectively validate prognostic biomarkers and identify tumors that might benefit from specific therapies.
INTRODUCTION
Primary high-grade (malignant) brain tumors account for only 1.4% of all cancers and 2.4% of all cancer deaths each year in the United States. 1 Although the cell of origin of primary brain tumors remains unknown, tumors are classified by histologic similarity to astrocytes (astrocytoma), oligodendrocytes (oligodendroglioma), or ependymal cells (ependymoma). The World Health Organization (WHO) classifies tumors based on histologic criteria, 2 with molecular markers increasingly being used to provide complementary information for diagnosis, prognostication, and predicting potential responsiveness to therapy. Gliomas are classified into four grades (I to IV) based on histology. Grade I and grade II gliomas, referred to as low-grade gliomas, are slow-growing tumors with a better prognosis. Highgrade gliomas are tumors diagnosed as grade III (anaplastic astrocytoma or anaplastic oligodendroglioma) or grade IV (glioblastoma). Glioblastomas represent approximately 60% of all highgrade gliomas, with an annual incidence of over 3 per 100,000. Approximately 10,000 new cases of glioblastoma and 4000 new cases of grade III glioma are diagnosed every year. Glioblastoma has a higher incidence in men, and the median age at diagnosis is 64 years for glioblastoma, 51 years for anaplastic astrocytoma, and 48 years for anaplastic oligodendroglioma. High-grade gliomas are diagnosed in patients of all ages, including in children. 1 The only known risk factor for the development of gliomas is exposure to ionizing radiation. 3 Other factors, including occupational or environmental exposures, head trauma, cell phone usage, and infections, have not been proven to cause brain tumors. Approximately 1% to 5% of high-grade gliomas occur in patients with genetic cancer syndromes such as Li-Fraumeni cancer syndrome and neurofibromatosis. The median overall survival of patients with glioblastoma is approximately 14 to 16 months, while the median overall survival of grade III gliomas varies by histology: 3 to 5 years for anaplastic astrocytoma and 15 years for anaplastic oligodendroglioma. 4, 5 Clinical prognostic factors include age, performance on the Karnofsky Performance Status Scale, and histology. In general, older patients, patients with poor performance status, and patients with higher-grade tumors have shorter survival.
Although the WHO classification system remains the primary criteria for diagnosis, molecular markers are becoming increasingly important in complementing diagnosis and providing important prognostic information. Mutation of the gene for the enzyme isocitrate dehydrogenase 1 or 2 (IDH1 or IDH2) is found in more than 70% of grade III anaplastic astrocytomas and anaplastic oligodendrogliomas. 6 Patients with newly diagnosed glioblastoma with IDH1 mutation are classified as secondary glioblastomas, ie, arising from a lower-grade tumor. IDH1 mutation confers a better prognosis but does not predict response to any specific treatment regimen. 7 Distinction between astrocytic and oligodendroglial tumors might be aided by detection of alpha thalassemia/mental retardation syndrome X-linked (ATRX) mutations in the former and telomerase reverse transcriptase (TERT) promoter mutations and 1p19q codeletion in the latter. 7 Molecular profiling of primary brain tumors has become an increasingly important area of research. Multiple glioma subtype classification schemes have been described demonstrating intratumoral and intertumoral heterogeneity. 8, 9 However, studies have failed to identify significant differences in outcome or response to specific therapy for these different subclasses. Only one molecular marker has been shown to predict response to chemotherapy. As described later in this article, patients with anaplastic oligodendroglioma tumors with loss of heterozygosity at chromosomes 1p and 19q have a twofold increase in survival when treated with radiation plus procarbazine, CCNU (lomustine), and vincristine (PCV) chemotherapy compared to patients treated with radiation alone.
DIAGNOSIS
Tumor location within the brain, rapidity of growth, and associated edema are responsible for the variability of presenting signs and symptoms of primary brain tumors. Fast-growing tumors with significant cerebral edema can lead to acute onset of symptoms, such as a focal neurologic deficit, seizures, intractable headaches, and nausea and vomiting from increased intracranial pressure. Slower-growing tumors are more likely to produce subtle changes in behavior or cognition only recognized in retrospect. Evaluation of the patient with a suspected primary brain tumor includes neuroimaging with CT or, preferably, MRI (Case 3-1). Infiltrative features, gadolinium contrast enhancement, the presence of blood, and diffusion restriction can be useful in differentiating primary from secondary (metastatic) tumors or infection. Magnetic resonance spectroscopy may aid in the diagnosis of high-grade gliomas in patients who are not optimal surgical candidates, such as patients with tumors in the eloquent cortex or the brainstem. However, examination of tissue following surgical resection or biopsy remains the gold standard for diagnosis.
PROGNOSTIC FACTORS Clinical Prognostic Factors
Traditionally, the prognosis of patients with high-grade gliomas has been based KEY POINTS h The signs and symptoms of primary brain tumors are dependent on the location within the brain and the rate of tumor growth. Slow-growing tumors are more likely to produce subtle changes in cognition and behavior, whereas fast-growing tumors are more likely to present acutely with intractable headache, nausea and vomiting, seizures, and focal neurologic deficits.
h Neuroimaging is essential in the early diagnosis of a primary brain tumor in the appropriate clinical context.
h Findings from CT, MRI, and magnetic resonance spectroscopy are all useful in increasing the suspicion of a primary brain tumor, but tissue diagnosis remains the gold standard and is essential for determining the optimal patient treatment.
Case 3-1
A 26-year-old right-handed woman with no significant past medical history developed new and progressively worsening headaches over the past 2 months. MRI demonstrated a right frontal infiltrating but nonenhancing lesion consistent with a glioma (Figure 3-1A and B) . The patient underwent a craniotomy with near gross total resection of the tumor (Figure 3-1C ), which was diagnosed as an isocitrate dehydrogenase 1 (IDH1) mutated anaplastic astrocytoma without loss of heterozygosity at chromosomes 1p and 19q. The patient received photon radiation to a total dose of 57 Gy in 30 fractions using intensity-modulated radiation therapy without concurrent chemotherapy. After the completion of radiation, she returned to work full time. Several years later, she became pregnant and celebrated the birth of her child. She was followed with serial imaging until 5 years after her initial diagnosis, when she was found to have an asymptomatic area of new enhancement in the 
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on clinical factors alone. For astrocytic tumors, the extent of enhancing tumor resection (based on MRI immediately postoperative), lower tumor grade, younger age (younger than 50 years), and good Karnofsky Performance Status Scale score are all favorable prognostic factors. For oligodendroglioma tumors, Pignatti and colleagues determined that poor prognosis was associated with age older than 40, astrocytoma histology, tumor larger than 6 cm, tumor crossing the midline, and evidence of neurologic deficits prior to surgery. There was no impact from extent of surgery. 10 The influence of tumor biology on outcome is likely to be equal or greater than these factors, as described in more detail below.
Molecular Prognostic Factors
Recent genomic studies have yielded several significant molecular prognostic factors. O-6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair protein that reverses the damage induced by alkylating agents such as temozolomide. Methylation of the MGMT gene promoter results in decreased expression of the enzyme, potentially rendering tumor cells more susceptible to alkylating agents. In retrospective analyses, a striking survival benefit was observed for those patients with MGMT promoter methylation who were treated with radiation therapy and temozolomide. 11, 12 However, patients with tumors that lack MGMT promoter methylation also appear to benefit from temozolomide. MGMT promoter methylation may predict benefit from temozolomide in elderly patients. 13, 14 Isocitrate dehydrogenase (IDH) mutations in gliomas are a positive prognostic factor, with an increase in overall survival noted in patients harboring an IDH mutation over those with wildtype IDH. 6 IDH mutations are observed in over 70% of lower-grade tumors and secondary glioblastomas, those tumors that result from malignant progression from an antecedent lower-grade tumor and account for approximately 5% of all glioblastomas. In low-grade gliomas, anaplastic gliomas, and glioblastomas, IDH mutation status appears to be one of the most important prognostic factors. 6, 15, 16 In anaplastic oligodendrogliomas, combined allelic losses of chromosomes 1p and 19q (1p19q loss of heterozygosity) have emerged as a prognostic marker of increased survival, as well as a predictive marker of chemotherapeutic efficacy. In seminal studies by both the European Organisation for Research and Treatment of Cancer (EORTC) and Radiation Comment. MRI offers the best noninvasive diagnostic tool for the diagnosis of a primary brain tumor. This patient's young age, the infiltrative and irregular borders of the lesion on MRI, and the absence of contrast enhancement on her initial MRI were strongly suggestive of a grade II or III tumor. Maximal safe surgical resection offered the best management to optimize overall survival and was essential for the diagnosis of, in this case, a grade III anaplastic astrocytoma. Following resection of a grade III anaplastic astrocytoma, the best management includes focused radiation. The use of chemotherapy in grade III anaplastic astrocytoma has not been proven to be superior to radiation alone. Because of the high risk of recurrence, serial imaging is appropriate. If new areas of enhancement are identified, re-resection is ideal to provide an accurate diagnosis and guide treatment; it also offers the opportunity for enrollment in clinical trials.
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Treatment Oncology Group (RTOG), patients with anaplastic oligodendrogliomas harboring the 1p19q loss of heterozygosity had a doubling of median survival when treated with combined radiation and chemotherapy compared to radiation therapy alone. Tumors without 1p19q loss of heterozygosity did not incur a survival benefit from the combined treatment. 17, 18 TREATMENT OF HIGH-GRADE GLIOMA The treatment of high-grade gliomas has greatly evolved over the past 30 years, but the three main tenets of therapy remain the same: maximal surgical resection, involved field external beam radiation therapy, and chemotherapy. The standard treatment for glioblastoma is supported by level I evidence from randomized phase 3 clinical trials. The optimal treatment of grade III astrocytic tumors is less clear, although recently completed and ongoing phase 3 clinical trials are rapidly shaping treatment decisions. For all recurrent tumors, very few treatment options exist and treatment patterns vary considerably, in part depending on patient access to clinical trials.
Supportive Therapy
Many patients with brain tumors present with signs or symptoms of increased intracranial pressure and have evidence of vasogenic edema on CT and MRI. Corticosteroids, such as dexamethasone, in doses ranging from 2 mg/d to 16 mg/d are often prescribed before surgery to reduce edema and minimize neurologic dysfunction. Long-term steroid use is not required in asymptomatic patients. Following surgery, efforts to discontinue steroids should be prioritized to minimize the long-term consequences of steroid use, such as myopathy, lymphopenia, infection risk, Cushing syndrome, and weight gain.
Patients presenting with seizures should be placed on antiepileptic drugs, with a special emphasis on nonYenzymeinducing anticonvulsants such as levetiracetam, lacosamide, valproic acid, and lamotrigine, which are less likely to interfere with chemotherapy metabolism than the first-generation anticonvulsants. Patients without prior history of seizures are not required to be placed on prophylactic antiepileptic agents, although the lifetime risk of seizures in a patient with glioblastoma approaches 80%. 19 Patients with glioblastomas have a high risk of developing lower extremity deep venous thrombosis (DVT) due to a hypercoagulable state and immobility caused by disease-related neurologic deficits and steroid usage. 20 The use of prophylactic anticoagulants is not recommended. However, there should be a low threshold for evaluation of DVT and pulmonary embolism (PE) in patients with primary brain tumors. In patients with proven DVT or PE, there is no contraindication for therapeutic anticoagulant dosing. Because of the shorter half-life and ease of reversibility, low-molecularweight heparinoids are preferred over oral warfarin therapy, especially in patients at risk of chemotherapy-induced thrombocytopenia and bleeding.
Surgery
The initial therapy in the management of high-grade gliomas remains safe, maximal surgical resection. Residual tumor is best assessed by contrast-enhanced MRI performed within 48 hours of surgical resection. Surgery can rapidly reduce mass effect and improve neurologic symptoms. Tumor tissue is required for accurate histologic diagnosis and treatment planning; it also may be used for genomic testing and prognostic marker evaluation (IDH mutation, MGMT promoter methylation, and 1p19q loss of heterozygosity status).
KEY POINTS
h The treatment for a newly diagnosed high-grade glioma includes maximal safe resection, radiation, and chemotherapy, either alone or in combination. The optimal treatment should take into consideration tumor grade, histology, and molecular characteristics, as well as the patient's age and Karnofsky Performance Status Scale score.
h Surgical resection is important not only for the relief of mass effect and for providing tissue for diagnosis, but a maximal extent of tumor resection is also associated with improved overall survival. Even in challenging locations, tumor tissue for diagnosis is essential for guiding appropriate therapy.
Multiple retrospective studies have confirmed the therapeutic importance and prognostic significance of gross total resection of the contrast-enhancing portion of the tumor. Longer overall survival is observed in patients with a greater extent of resection. 21, 22 The use of the fluorescent marker 5-aminolevulinic acid while operating under blue light may enhance the rate of gross total resection and progression-free survival. 23 When maximal resection is not feasible owing to tumor location in eloquent cortex or the brainstem, all efforts should be made to obtain adequate tissue for diagnosis and molecular evaluation. Infiltrating gliomas are not surgically curable, and remaining nonenhancing tumor as visualized on T2 and fluidattenuated inversion recovery (FLAIR) sequences contributes to residual tumor volume for purposes of clinical trial evaluation, as well as being the focus for targeting radiation therapy. 24 
Radiation
Of the three main treatment modalities, radiation remains the most important and relatively efficacious therapy for primary brain tumors. Fractionated localized radiation therapy is part of the standard treatment for all high-grade gliomas. Photon radiation is delivered to the involved field, targeting the primary lesion plus a 1-cm to 3-cm margin to treat infiltrating tumor. The standard dose of radiation for glioblastoma is 60 Gy, delivered in 30 to 33 fractions of 1.8 Gy to 2 Gy. 25 All high-grade tumors, including both anaplastic gliomas and glioblastomas, are treated to a total dose of 54 Gy to 60 Gy. However, radiation given concurrently with temozolomide has only been proven to improve outcome in patients with glioblastomas 11 and is not currently considered standard treatment for patients with grade III tumors. Higher radiation doses have not been shown to be more efficacious. Patients are routinely given Pneumocystis jiroveci prophylaxis during combined treatment with chemotherapy and radiation, with either thrice weekly trimethoprim-sulfamethoxazole or daily dapsone. In elderly patients or patients with a poor performance status, hypofractionated regimens (eg, 40 Gy in 15 fractions) can be utilized. 26 In one clinical trial, lower total radiation therapy doses (50 Gy) was superior to best supportive care alone in patients older than 70 years of age. 27 Techniques such as intensity-modulated radiation therapy are commonly used to limit radiation exposure to uninvolved normal brain tissue. Novel therapeutic approaches, including the use of protons and neutrons, are currently under investigation but do not have a proven role in the management of gliomas.
Chemotherapy
Chemotherapy is increasingly becoming an integral component of the treatment of high-grade gliomas, including both glioblastomas and anaplastic oligodendrogliomas. The inclusion of chemotherapy into the initial management of both of these tumor types has dramatically improved median overall survival. Temozolomide, an oral cytotoxic DNA-alkylating chemotherapy, is now a critical part of the standard treatment for glioblastoma. Concomitant radiation and temozolomide followed by adjuvant temozolomide for 6 months significantly improved overall survival compared to radiation alone in a large randomized phase 3 clinical trial. 11 Patients treated with the combination of radiation plus temozolomide had a statistically significant improvement in median overall survival compared to those treated with radiation alone (14.6 months versus 12.1 months) and a twofold increase in the 2-year survival rate, from 10.4% to 26 the lasting benefit of this approach at 5 years. A companion study demonstrated that patients whose tumors had MGMT promoter methylation had a better prognosis, with a 46% median overall survival at 2 years. 12 Recent studies have confirmed the benefit of radiation concomitant with temozolomide. Although prolonged adjuvant temozolomide exposure (21 days versus 5 days per month) did not demonstrate an improvement in median overall survival compared to standard dose, the prognostic significance of MGMT was demonstrated. 4 Owing to the overall poor prognosis for elderly patients with glioblastoma, alternative approaches have been investigated in patients older than 65 years of age. Two trials of patients in this age group demonstrated a poor median overall survival of 7 to 9 months. MGMT promoter methylation was strongly predictive of benefit from temozolomide, suggesting that patients with a methylated MGMT may be treated with chemotherapy alone, while patients with an unmethylated MGMT can receive radiation therapy alone. 13, 14 Because of the excitement surrounding the efficacy of bevacizumab in patients with recurrent glioblastoma, two recently completed large randomized phase 3 trials, Avastin in Glioblastoma (AVAglio) and RTOG 0825, evaluated the efficacy of the addition of bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), to up-front treatment with radiation and temozolomide. These studies confirmed that the addition of bevacizumab conferred no benefit in terms of overall survival in patients with newly diagnosed glioblastoma when compared to the standard treatment arm, although prolongation of progression-free survival was observed. 28, 29 Although no patient subgroups were demonstrated to derive a greater benefit from this approach, ongoing analyses are attempting to identify molecular subgroups that benefited from the addition of bevacizumab. A recent phase 3 clinical trial of adding integrintargeted therapy to the standard treatment did not appear to provide any additional benefit. In the absence of access or eligibility for enrollment into a clinical trial, radiation with concurrent temozolomide followed by adjuvant temozolomide remains the standard treatment for the majority of patients with glioblastomas.
The standard treatment for patients with grade III anaplastic gliomas depends on the presence of 1p19q codeletion, which is largely confined to tumors with classic anaplastic oligodendroglioma histology. For patients with 1p19q codeleted tumors, adjuvant treatment should include both radiation and chemotherapy. This approach is supported by two large international phase 3 clinical trials for patients with anaplastic oligodendroglioma tumors, in which the addition of chemotherapy (PCV) to radiation led to a significant prolongation of progression-free and overall survival in those with 1p19q codeleted tumors. 17, 18 The benefit of this threedrug combination was observed when administered before or after radiation, although the optimal timing is not known (Case 3-2). Although temozolomide is frequently used in place of PCV because of ease of administration and lower side effect profile, its efficacy has not been adequately evaluated. 30 The optimal treatment of grade III tumors without 1p19q codeletion is less studied. Anaplastic oligodendroglioma tumors without 1p19q codeletion that are IDH1 or IDH2 mutant also significantly benefit from radiation plus PCV chemotherapy. 31 Patients with astrocytic tumors without 1p19q codeletion should receive postoperative radiation. Adjuvant temozolomide has no proven KEY POINTS h After surgical resection, the standard treatment for glioblastoma includes radiation combined with temozolomide, followed by 6 to 12 cycles of adjuvant temozolomide chemotherapy.
h For patients with anaplastic oligodendroglioma tumors with 1p19q loss of heterozygosity, the use of both radiation and procarbazine, CCNU (lomustine), and vincristine (PCV) chemotherapy dramatically increases progression-free and overall survival compared with radiation alone and should be considered as the standard treatment for all newly diagnosed patients with 1p19q loss of heterozygosity anaplastic oligodendroglioma.
role in this latter group. Given the overall better prognosis of grade III astrocytic tumors and the absence of proven benefit, consideration should be given to deferring adjuvant chemotherapy. An ongoing phase 3 clinical trial is evaluating the optimal combina-tion and schedule of radiation and chemotherapy in these patients.
RECURRENT DISEASE
The approach to the patient with recurrent tumor will vary widely depending on multiple factors, such
Case 3-2
A 50-year-old right-handed man was in his usual state of health until he was assaulted, resulting in a head injury. The patient briefly lost consciousness and was taken to a local hospital where he underwent evaluation with imaging. MRI revealed a left frontal lesion initially considered a stroke or contusion. Imaging and reevaluation 2 months later suggested the lesion was more consistent with a primary brain tumor (Figure 3-2A and B) . The patient underwent a gross total resection of tumor (Figure 3-2C) , with the pathology showing anaplastic oligodendroglioma with loss of heterozygosity at chromosomes 1p and 19q. The patient underwent radiation with intensity-modulated radiation therapy to a total dose of 57 Gy in 30 fractions, followed by six cycles of procarbazine, CCNU (lomustine), and vincristine (PCV) chemotherapy. The patient had no neurologic deficits and continued to work full time from the time of diagnosis. He showed no evidence of tumor recurrence 7 years later.
Comment. Advanced imaging technology is leading to an increase in the incidental diagnosis of primary brain tumors, as in this case of the patient who had experienced head trauma. Although both stroke and contusions are common following head trauma, early reimaging is important when the imaging findings are not consistent with these diagnoses. The imaging in this case was strongly suggestive of a primary brain tumor, and the correct decision to proceed with surgery was made in a timely manner. The molecular analysis of this tumor was essential since anaplastic oligodendroglioma tumors with 1p19q loss of heterozygosity have been shown to have a better prognosis and, more important, to be sensitive to chemotherapy. This patient was appropriately treated with both radiation and PCV chemotherapy. Because primary brain tumors are not curable, continued surveillance is warranted to identify recurrence of disease. as the location of the recurrence, the patient's Karnofsky Performance Status Scale score, prior treatment experience, and access to clinical trials. Ultimately, all grade III astrocytic tumors will progress into glioblastomas, although this appears to be very rare with grade III oligodendrogliomas. In the recurrent setting, there may be an indication for repeat surgery, especially in patients whose recurrent tumor exerts an acute mass effect or if a question exists about the nature of the imaging change (recurrent tumor versus treatment effect). Histologic evidence of glioblastoma in a patient with prior grade III tumor could allow for enrollment onto a clinical trial. No prospective data are available to confirm a positive impact of repeat surgery on overall survival.
Patients with recurrent glioblastoma are often rechallenged with standard dose or alternative schedules of temozolomide. Clinical data from the Canadian RESCUE study supports rechallenge with doseintense temozolomide if patients have been stable off adjuvant temozolomide for more than 2 months. However, in patients with disease progression after six cycles and during treatment with temozolomide, there was no benefit of alternate dosing of temozolomide when failing standard dose temozolomide. 32 However, treatment with other alkylating agents, such as CCNU, following progression on temozolomide is a viable therapeutic option. For patients progressing after temozolomide and CCNU chemotherapy, no chemotherapy regimen has been established and patients are best treated on clinical trials.
Targeting angiogenesis in glioblastoma is an attractive approach to treating this disease given the highly vascularized nature of glioblastoma. In March 2009, the anti-VEGF antibody bevacizumab was given accelerated approval by the US Food and Drug Administration (FDA) as monotherapy for the treatment of recur-rent glioblastoma. This approval was based on two independent studies conducted in the United States, both showing an improvement in response rates and 6-month progression-free survival compared with historical controls (in the absence of a nonYbevacizumabcontaining control arm in either clinical trial). 33, 34 The benefit of this therapy might be mostly associated with the steroid-sparing effect and reduction in cerebral edema (Case 3-3). Determination of response and progression in patients treated with antiangiogenic therapy is challenging because of the impact of the therapy on vascular permeability and resultant decrease in contrast enhancement. New imaging criteria (Response Assessment in Neuro-Oncology, or RANO) have improved the accuracy of imaging-based determination of progression, although additional improvements are needed. 24 Although there does not appear to be a survival benefit of single-agent bevacizumab compared to historical controls, recent data from a randomized trial by the EORTC suggest that the combination of bevacizumab with CCNU improves overall survival compared to either agent alone. 35 These results remain to be established in a large randomized phase 3 clinical trial.
One option considered for patients who progress 1 or more years following their initial diagnosis is reirradiation. This is more feasible when the tumor recurrence is small or in a location distant from the original site of radiation. No prospective clinical trials exist, and the few limited series to date do not allow definitive conclusions on the efficacy of this approach.
TRENDS
Because of the poor prognosis of recurrent glioblastoma, a large effort was launched to better understand the molecular biology of tumorigenesis and the drivers leading to oncogenesis and sustained tumor growth. The genomic analyses described by The Cancer h Bevacizumab monotherapy is approved for the treatment of recurrent glioblastoma. The antipermeability effect of antiangiogenic therapy results in reduction in cerebral edema and contrast enhancement and may allow for tapering of corticosteroids. Determination of progression is challenging owing to potential delay in the redevelopment of contrast enhancement and subtle T2/fluid-attenuated inversion recovery (FLAIR) nonenhancing tumor progression.
Case 3-3
A 62-year-old previously healthy woman reported a 2-month history of left-sided numbness. MRI (Figure 3-3A and B) revealed a ring-enhancing intracranial mass in the deep right parietal region. She underwent a biopsy; the pathology was consistent with glioblastoma. She was treated with radiation to 60 Gy with concurrent temozolomide, followed by five cycles of adjuvant temozolomide. During her sixth cycle, she developed progressive left-sided weakness, with MRI demonstrating significant cerebral edema, mass effect, and enlargement of the enhancing lesion ( Figure 3-3C and D) . Despite corticosteroid administration, the patient's condition worsened. Bevacizumab was initiated in combination with CCNU (lomustine) chemotherapy on clinical trial. MRI showed improvement in the cerebral edema and contrast enhancement, but fluid-attenuated inversion recovery (FLAIR) images 
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Genome Atlas (TCGA) project have uncovered that glioblastomas are associated with alterations in three core overlapping pathways: (1) receptor tyrosine kinase/RAS/phosphatidylinositol 3-kinase (RTK/RAS/PI3K) signaling (altered in 90% of glioblastomas); (2) p53 signaling (altered in 86% of glioblastomas); and (3) retinoblastoma signaling (altered in 79% of glioblastomas). 8 In the RTK/PI3K pathway, phosphatase and tensin homolog (PTEN) deletions and mutations were frequent, as were aberrations in epidermal growth factor receptor (EGFR), v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2), platelet-derived growth factor receptor, alpha polypeptide (PDGFRA), and MET proto-oncogene, receptor tyrosine kinase (MET). Dysregulation of the retinoblastoma pathway most commonly occurred with deletion of cyclin-dependent kinase inhibitor 2A (CDKN2A) locus on chromosome 9p21, followed by cyclindependent kinase 4 (CDK4) locus amplification. Ongoing efforts are under way to inhibit these signaling nodes, but, to date, single-agent molecularly targeted therapies have been largely ineffective despite promising preclinical data. This may be, in part, because of the molecular heterogeneity of gliomas that has rendered the development of targeted therapy more challenging than previously appreciated.
Tumor heterogeneity is both intertumoral and intratumoral, further complicated by the accumulation of additional molecular changes over time. The molecular profile from tumor recurrence is distinctly different as a result of accumulated genomic alterations. In a recent mutational analysis performed on paired glioma samples, in 43% of the cases, at least half of the mutations in the initial tumor were undetected at recurrence, including driver mutations in tumor protein p53 (TP53), ATRX, SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 4 (SMARCA4), and B-Raf proto-oncogene, serine/threonine kinase (BRAF). 36 The impact of temozolomide on the mutational profile of recurrent tumors was examined, revealing hypermutated tumors harboring driver mutations in the retinoblastoma and Akt-mTOR pathways. 36 These findings demonstrate an evolving genomic landscape from time of diagnosis to recurrence and highlight the difficulty of developing targeted therapies in the setting of progressive disease.
The development of targeted therapy is complicated by the complexity and redundancy of signaling pathways. The lack of effectiveness of single-agent therapies is likely attributable to the tumor's capability to utilize multiple cellular pathways in a redundant fashion, KEY POINTS h The expression of a target may not predict the responsiveness of a tumor to target inhibition because of differences in patient populations, genetic heterogeneity within the tumor, and the relative inefficiency of the small molecule in reaching and inhibiting the target.
h Recurrent glioblastoma is a genetically heterogeneous tumor, and a complete understanding of the drivers of tumor growth in this setting is lacking. demonstrated significant residual tumor (Figure 3-3E and F) . After starting the clinical trial, the patient remained independent in her activities of daily living but used a walker for ambulation.
Comment. The median time to tumor recurrence in patients with glioblastoma is approximately 4 to 6 months following their original diagnosis. Poor performance, minimal resection (biopsy in this case), and older age were all poor prognostic factors and heralded tumor recurrence in this patient. Options remain limited for patients with recurrent glioblastoma, especially when recurrence is rapid, is associated with significant neurologic deficits, and occurs within the first year of diagnosis. Because of significant cerebral edema, mass effect, and rapid clinical deterioration, this patient was treated with bevacizumab, which rapidly reduced vascular permeability and reduced cerebral edema. Antiangiogenic therapies are not antitumor in nature but, when used in combination with cytotoxic chemotherapy, may lead to prolongation of progression-free survival.
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underscoring the need to investigate the combination of targeted therapies with other agents, both targeted and less targeted. Preclinical studies are paving the way for the development of combination strategies that inhibit the driver pathway together with the resistance pathways that develop after singleagent therapy. Use of multiagent drug combinations is likely to minimize resistance to treatment and enhance the efficacy of targeted therapy. Multiple clinical trials are underway to explore the potential to target these pathways alone or in combination.
CONCLUSION
High-grade gliomas are some of the most challenging cancers to treat because of their infiltrative nature, location within the brain that limits maximal resection, and limited therapies to target their heterogeneous complex biology. Recent advances in imaging, molecular genetics, and targeted molecular therapies are bringing hope to patients diagnosed with this deadly disease.
